HCC1937 Xenograft Model Service for Breast Cancer

The HCC1937 xenograft model serves as a highly specialized in vivo translational platform designed to evaluate therapeutic candidates targeting BRCA1-mutated, triple-negative breast cancers. Alfa Cytology delivers a comprehensive, end-to-end HCC1937 xenograft model service, integrating fully authenticated cellular assets with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of HCC1937 Xenograft Model for Breast Cancer

The HCC1937 cell line is a highly valuable human mammary carcinoma model, renowned in research as the first breast cancer cell line derived from a patient carrying a germline BRCA1 mutation (specifically a homozygous 5382insC mutation in exon 20). Originally isolated from a primary ductal carcinoma, this model exhibits a classic Triple-Negative Breast Cancer (TNBC) molecular phenotype, characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Because of its inherent defect in DNA double-strand break repair via homologous recombination, HCC1937 is an indispensable discovery tool for evaluating novel PARP inhibitors, platinum-based chemotherapies, and targeted strategies utilizing synthetic lethality concepts.

When established in vivo as a xenograft in immunodeficient mice, HCC1937 cells form solid tumors that faithfully recapitulate the genomic instability, distinct histopathological architecture, and microenvironmental factors seen in human BRCA-deficient breast malignancies. This model typically requires expert handling and optimized cell preparation methodologies to overcome variable growth features and establish consistent kinetics.

Fig 1. HCC1937/luc2 TNBC tumors and metastatic nodules detected by BLI in vivo imaging. (Ramos-Gonzalez MR, et al., 2024)

Cell Line Information: HCC1937

The HCC1937 cell line maintains a stable epithelial-like morphology in vitro and reliably preserves its signature BRCA1 mutation status upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC1937 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC1937 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in BRCA1-mutated triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC1937 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC1937 xenograft model:

• Cell Culture & Quality Control: HCC1937 cells are cultivated in specialized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HCC1937 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. HCC1937 Xenograft Model Construction Workflow

Case Study - HCC1937 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC1937 xenograft model was successfully utilized to evaluate the efficacy of a next-generation PARP inhibitor candidate. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your BRCA-mutated triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models, ensuring high translational relevance for diverse oncology pipelines.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling and contamination screening, to secure baseline phenotypic and genetic stability.
• Exceptional Technical Reproducibility: Highly optimized inoculation methodologies and standardized laboratory workflows designed to achieve uniform tumor growth kinetics and minimize intra-group variance.
• Comprehensive Downstream Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking, histopathology (IHC/IF), biomarker evaluation, and specialized PK/PD tissue processing.
• Rigorous Scientific Integrity: All studies are executed by a specialized oncology team adhering strictly to international standards, providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against BRCA-mutated triple-negative breast cancer using the robust HCC1937 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please reach out to us today to speak directly with an oncology specialist, or contact us to request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.